Yale YODA Project announces first availability of medical device trial data

January 14, 2015, Yale University
Credit: Shutterstock/Yale University

The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made possible through collaboration with Johnson & Johnson.

In this groundbreaking move, results from the clinical trails of the Medical Devices and Diagnostics businesses of Johnson & Johnson will be made available to researchers through an agreement with the Yale YODA Project. This establishes a fully independent intermediary to manage requests and promote data use, just as it has done with its pharmaceutical .

The YODA Project will continue to act as a bridge between investigators and Johnson & Johnson's pharmaceutical and device and diagnostics businesses. Under the arrangement, the YODA Project will approve or deny requests from investigators for de-identified patient data associated with the pharmaceutical, medical device, and diagnostic conducted by Johnson & Johnson companies. This expanded scope that now includes device and diagnostic studies is another step forward in the continuing evolution of open science in clinical medicine.

"This action will benefit society and represents a major step forward in the effort to promote , as Johnson & Johnson's leadership in this area now extends from sharing its drug data to sharing its device and diagnostics data," said Dr. Harlan Krumholz, professor of medicine and leader of the YODA Project. "We hope this action serves as a catalyst to others to join the momentum on open science."

Dr. Joseph Ross, associate professor of medicine and member of the YODA Project, added, "Data sharing maximizes knowledge generation from clinical research studies, enabling multiple investigators to use the data for additional research projects. Through sharing of clinical trial data for , we can now learn more about these important medical treatments."

Dr. Joanne Waldstreicher, chief medial officer of Johnson & Johnson said, "Sharing data from clinical trials leads to greater insights in medicine. This agreement with the YODA Project underscores Johnson & Johnson's commitment to responsibly share clinical trial data with researchers in a way that we believe advances medical science and public health."

Requests for data may be directly submitted to the YODA Project through its website.

Explore further: Safety review of bone growth product ushers in new era of data sharing

Related Stories

Safety review of bone growth product ushers in new era of data sharing

June 17, 2013
A Yale project involving the independent review of a bone growth product's safety has yielded results, which are published in the June 18 issue of Annals of Internal Medicine. The findings are part of the Yale University ...

Data sharing in pharmaceutical industry shows progress

October 16, 2014
To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Johnson & Johnson plans Ebola vaccine testing

October 22, 2014
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.

Johnson & Johnson buying Alios for $1.75B

September 30, 2014
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.

Recommended for you

Drug overdose epidemic goes far beyond opioids, requires new policies

November 7, 2018
Most government-funded initiatives to address the overdose epidemic in the United States have targeted opioids specifically and have neglected other drugs that are increasingly implicated in overdoses, such as cocaine and ...

Zebrafish larvae help in search for appetite suppressants

November 2, 2018
Researchers at the University of Zurich and Harvard University have developed a new strategy in the search for psychoactive drugs. By analyzing the behavior of larval zebrafish, they can filter out substances with unwanted ...

FDA OKs powerful opioid pill as alternative to IV painkiller

November 2, 2018
U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals.

Amphetamine-related hospitalizations surged between 2003 and 2015

November 2, 2018
An analysis conducted by Hennepin Healthcare, University of Minnesota School of Public Health and University of Michigan researchers shows amphetamine-related hospitalizations increased more than 270 percent from 2008 to ...

Cocaine-fentanyl overdoses underscore need for more 'test strips' and rapid response

November 1, 2018
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health ...

Combination drug targeting opioid system may help relieve symptoms of major depression

October 29, 2018
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment. The results of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.